CTI BioPharma Announces Presentations at the 63rd American Society of Hematology Meeting

Rhea-AI Summary

CTI BioPharma Corp. (Nasdaq: CTIC) announced five poster presentations for its pacritinib program at the 63^rd American Society of Hematology Annual Meeting & Exposition, taking place from December 11-14, 2021, in Atlanta, Georgia. The abstracts include a head-to-head comparison of pacritinib and ruxolitinib, safety analysis, long-term treatment outcomes, symptom impact from the Persist-2 study, and evidence of NF-κB pathway activation in advanced myelofibrosis. These findings may contribute significantly to the understanding and treatment of blood-related cancers.

Positive

• Five presentations on pacritinib at a major conference could enhance visibility and credibility in the hematology field.
• The focus on specific clinical outcomes may attract interest from investors and medical professionals.

Negative

• None.

SEATTLE, Nov. 4, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced five poster presentations from the Company's pacritinib program at the 63^rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually and in Atlanta, Georgia, December 11-14, 2021.

The details of the poster presentations are as follows:

Abstract Title: A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia
Publication Number: 3639 
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 13, 2021
Presentation Time: 6:00–8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5
Presenter: Dr. John Mascarenhas

Abstract title: Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia
Publication Number: 3640 
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 13, 2021
Presentation Time: 6:00 p.m.–8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5
Presenter: Dr. John Mascarenhas

Abstract Title: Long-Term Treatment with Pacritinib on a Compassionate Use Basis in Patients with Advanced Myelofibrosis
Publication Number: 3649 
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 13, 2021
Presentation Time: 6:00 p.m.–8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5
Presenter: Dr. (Professor) Claire Harrison

Abstract title: The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study
Publication Number: 3628
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 13, 2021
Presentation Time: 6:00 p.m.–8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5
Presenter: Dr. Jeanne Palmer

Abstract title: Evidence of NF-ΚB Pathway Activation in Patients with Advanced, High Molecular Risk Myelofibrosis
Publication Number: 3584 
Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III
Session Date: Monday, December 13, 2021
Presentation Time: 6:00–8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5
Presenter: Dr. Jennifer O'Sullivan

The full abstracts can be viewed here.

About Pacritinib

Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1 and CSF1R, but not JAK1. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT.

About CTI BioPharma Corp.

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on developing and commercializing pacritinib, our product candidate currently in active late-stage development. We are headquartered in Seattle, Washington.

CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-presentations-at-the-63rd-american-society-of-hematology-meeting-301416611.html

SOURCE CTI BioPharma Corp.

FAQ

What presentations will CTIC give at the ASH Annual Meeting?

CTIC will present five abstracts related to pacritinib, focusing on various aspects of myelofibrosis treatment.

When is the ASH Annual Meeting where CTIC will present?

The 63rd ASH Annual Meeting will be held from December 11-14, 2021.

What is pacritinib's role in treating myelofibrosis?

Pacritinib is an investigational oral kinase inhibitor targeted for patients with myelofibrosis, especially those with severe thrombocytopenia.

Where can I access the full abstracts presented by CTIC?

The full abstracts are available on the ASH meeting website and can be accessed through the provided links in the press release.

What type of company is CTI BioPharma?

CTI BioPharma focuses on developing and commercializing targeted therapies for blood-related cancers.